Armando Stabile, MD

Vita-Salute San Raffaele University

Disclosure information not submitted.

Presentation(s):

• MP15-19: Can low risk disease outside the Index lesion be left untreated in men suitable for focal therapy? Development of Novel criteria to identify potential candidates for focal therapy among patients with intermediate risk prostate cancer and positive multi-parametric MRI.

  Friday, May 13, 2022
  2:45 PM – 4:00 PM

• PD41: Prostate Cancer: Detection & Screening IV

  Sunday, May 15, 2022
  9:30 AM – 11:30 AM

• MP51-07: The prognostic value of the number of positive targeted cores in men with positive multiparametric magnetic resonance imaging of the prostate. Results from a large, multi-institutional series.

  Sunday, May 15, 2022
  4:30 PM – 5:45 PM

• MP51-08: Does a positive multi-parametric MRI always warrant prostate biopsy? The importance of integrating clinical and imaging data based on a large, multi-institutional series.

  Sunday, May 15, 2022
  4:30 PM – 5:45 PM

• MP51-11: Has the introduction of mpMRI in the diagnostic pathway of prostate cancer led to improved oncological outcomes after radical prostatectomy? Result from a large single-institutional series.

  Sunday, May 15, 2022
  4:30 PM – 5:45 PM

• MP53-01: Detection of clinically significant prostate cancer in mpMRI visible lesions: Size matters. Results from a large, two-institutional series.

  Monday, May 16, 2022
  7:00 AM – 8:15 AM